Lake Street Capital cut shares of Diplomat Pharmacy (NYSE:DPLO) from a buy rating to a hold rating in a research report released on Tuesday morning, MarketBeat Ratings reports. They currently have $15.00 target price on the stock, down from their prior target price of $30.00.

A number of other equities analysts also recently weighed in on DPLO. William Blair downgraded Diplomat Pharmacy from an outperform rating to a market perform rating in a research report on Monday. Zacks Investment Research downgraded Diplomat Pharmacy from a hold rating to a strong sell rating in a research report on Thursday, January 3rd. Robert W. Baird upgraded Diplomat Pharmacy from an underperform rating to a neutral rating and upped their price objective for the stock from $10.00 to $15.00 in a research note on Friday, December 7th. Morgan Stanley dropped their price objective on Diplomat Pharmacy from $20.00 to $18.00 and set an equal weight rating on the stock in a research note on Monday, December 3rd. Finally, Mizuho dropped their price objective on Diplomat Pharmacy to $18.00 and set a neutral rating on the stock in a research note on Friday, November 9th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $22.70.

Shares of Diplomat Pharmacy stock traded down $0.06 during trading on Tuesday, hitting $13.14. 15,370 shares of the company were exchanged, compared to its average volume of 868,337. The firm has a market capitalization of $997.22 million, a P/E ratio of 15.64 and a beta of 0.97. Diplomat Pharmacy has a 1-year low of $12.30 and a 1-year high of $28.74. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.21). Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.42 billion. During the same quarter in the prior year, the firm posted $0.01 earnings per share. Diplomat Pharmacy’s revenue for the quarter was up 22.0% compared to the same quarter last year. Research analysts anticipate that Diplomat Pharmacy will post 0.8 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group boosted its stake in Diplomat Pharmacy by 1,245.2% in the third quarter. Rehmann Capital Advisory Group now owns 4,076 shares of the company’s stock valued at $210,000 after buying an additional 3,773 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its stake in Diplomat Pharmacy by 142.2% in the third quarter. Public Employees Retirement Association of Colorado now owns 6,307 shares of the company’s stock valued at $122,000 after buying an additional 3,703 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new stake in Diplomat Pharmacy in the third quarter valued at about $340,000. United Services Automobile Association acquired a new stake in Diplomat Pharmacy in the second quarter valued at about $210,000. Finally, Raymond James & Associates acquired a new stake in Diplomat Pharmacy in the second quarter valued at about $244,000. 85.22% of the stock is currently owned by institutional investors and hedge funds.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: When is a capital gain realized?

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.